Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 18Carcinoma, Non-Small-Cell Lung 10Carcinoma, Renal Cell 9Kidney Neoplasms 4Stomach Neoplasms 3Mesothelioma 3Lung Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Carcinoma, Hepatocellular 3Skin Neoplasms 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Various Advanced Cancer 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Non-Small Cell Lung Cancer Metastatic 1Neoplasms 1Melanoma, Cutaneous Malignant 1Lymphatic Metastasis 1

Interventions

Gemcitabine 3Cisplatin 3Carboplatin 3pembrolizumab 2vinflunine 1tremelimumab 1erdafitinib 1enfortumab vedotin 1durvalumab 1Nivolumab 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Urothelial Cancer × Ipilimumab × Clear all
NCT03036098 2026-03-06

CheckMate901

Bristol-Myers Squibb

Phase 3 Active not recruiting
1,314 enrolled 23 charts 1 FDA
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡